418 related articles for article (PubMed ID: 16889431)
1. Apomorphine in dopaminergic therapy.
Subramony JA
Mol Pharm; 2006; 3(4):380-5. PubMed ID: 16889431
[TBL] [Abstract][Full Text] [Related]
2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
3. Controlled-release transdermal apomorphine treatment for motor fluctuations in Parkinson's disease.
Priano L; Albani G; Calderoni S; Baudo S; Lopiano L; Rizzone M; Astolfi V; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
Neurol Sci; 2002 Sep; 23 Suppl 2():S99-100. PubMed ID: 12548362
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
5. Treatments for Parkinson disease--past achievements and current clinical needs.
Poewe W
Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA: from a biologically inactive amino acid to a successful therapeutic agent.
Hornykiewicz O
Amino Acids; 2002; 23(1-3):65-70. PubMed ID: 12373520
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
8. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease.
Kolls BJ; Stacy M
Clin Neuropharmacol; 2006; 29(5):292-301. PubMed ID: 16960475
[TBL] [Abstract][Full Text] [Related]
10. Addiction to apomorphine: a clinical case-centred discussion.
Téllez C; Bustamante ML; Toro P; Venegas P
Addiction; 2006 Nov; 101(11):1662-5. PubMed ID: 17034447
[TBL] [Abstract][Full Text] [Related]
11. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
12. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
13. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease.
Priano L; Albani G; Brioschi A; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Scaglione F; Fraschini F; Bergamasco B; Mauro A
Mov Disord; 2004 Aug; 19(8):937-42. PubMed ID: 15300660
[TBL] [Abstract][Full Text] [Related]
14. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
15. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
16. The pragmatic use of apomorphine at the end of life.
Dewhurst F; Lee M; Wood B
Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
[TBL] [Abstract][Full Text] [Related]
17. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
[TBL] [Abstract][Full Text] [Related]
18. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
Obering CD; Chen JJ; Swope DM
Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
[TBL] [Abstract][Full Text] [Related]
19. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
20. [Shifting to subcutaneous infusion of apomorphine in advanced Parkinson's disease patients on an out-patient basis: experience and recommendations].
Castaño B; Mateo D; Giménez-Roldán S
Neurologia; 2007 Apr; 22(3):133-7. PubMed ID: 17364250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
